

**Claims**

- 1 A diblock copolymer of formula A-B wherein  
polymer block A represents a linear pharmaceutically acceptable hydrophilic  
polymer with a molecular weight < 1,000, and
- 5 polymer block B represents a polymer comprising at least two different monomers  
selected from glycolic acid, propiolactone,  $\gamma$ -butyrolactone,  $\delta$ -valerolactone,  $\gamma$ -  
valerolactone,  $\epsilon$ -caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene  
carbonate,  $\epsilon$ -lactone, 1,5-dioxepan-2-one characterized in that the diblock  
copolymer is liquid at a temperature below 50°C.
- 10
- 2 A diblock copolymer according to claim 1 wherein polymer block B represents a  
polymer comprising monomers selected from glycolic acid, propiolactone,  
 $\gamma$ -butyrolactone,  $\delta$ -valerolactone,  $\epsilon$ -caprolactone, trimethylene carbonate,  
p-dioxanone, tetramethylene carbonate,  $\epsilon$ -lactone, 1,5-dioxepan-2-one or mixtures  
15 thereof.
3. A diblock copolymer according to claim 1 wherein polymer block B represents a  
polymer comprising monomers of trimethylene carbonate and monomers selected  
from glycolic acid, propiolactone,  $\gamma$ -butyrolactone,  $\delta$ -valerolactone,  $\gamma$ -  
20 valerolactone,  $\epsilon$ -caprolactone, p-dioxanone, tetramethylene carbonate,  $\epsilon$ -lactone,  
1,5-dioxepan-2-one or mixtures thereof.
4. A diblock copolymer according to claim 3 wherein polymer block B represents a  
polymer comprising monomers of trimethylene carbonate and monomers selected  
25 from glycolic acid, propiolactone,  $\gamma$ -butyrolactone,  $\delta$ -valerolactone,  
 $\epsilon$ -caprolactone, p-dioxanone, tetramethylene carbonate,  $\epsilon$ -lactone, 1,5-dioxepan-2-  
one or mixtures thereof.
5. A diblock copolymer according to claim 1 wherein polymer block B represents a  
polymer comprising monomers selected from propiolactone,  $\gamma$ -butyrolactone,  
30  $\delta$ -valerolactone,  $\gamma$ -valerolactone,  $\epsilon$ -caprolactone, trimethylene carbonate,  
p-dioxanone, tetramethylene carbonate,  $\epsilon$ -lactone, 1,5-dioxepan-2-one.
6. A diblock copolymer according to claim 5 wherein polymer block B comprises  
35 two different monomers selected from propiolactone,  $\gamma$ -butyrolactone,  
 $\delta$ -valerolactone,  $\gamma$ -valerolactone,  $\epsilon$ -caprolactone, trimethylene carbonate,

**BEST AVAILABLE COPY**

p-dioxanone, tetramethylene carbonate,  $\epsilon$ -lactone, 1,5-dioxepan-2-one.

- 5
7. A diblock copolymer according to claim 6 wherein polymer block B comprises monomers selected from  $\epsilon$ -caprolactone and trimethylene carbonate.
8. A diblock copolymer according to any one of claims 1 to 7 wherein polymer block A represents poly(C<sub>1-20</sub>alkylene oxide) or a derivative thereof.
- 10
9. A diblock copolymer according to claim 8 wherein the poly(C<sub>1-20</sub>alkylene oxide) or the derivative thereof is poly(ethylene glycol) or a derivative thereof, in particular poly(ethylene glycol) monomethylether.
- 15
10. A diblock copolymer according to claim 9 wherein the poly(ethylene glycol) or a derivative thereof has a molecular weight ranging from > 350 to  $\leq$  750.
11. A diblock copolymer according to claim 10 wherein the poly(ethylene glycol) or the derivative thereof has a molecular weight of 750.
- 20
12. A diblock copolymer according to any one of claims 1 to 11 having a molecular weight ranging from 2,000 to 10,000.
13. A diblock copolymer according to claim 12 having a molecular weight ranging from 2,000 to 8,000.
- 25
14. A diblock copolymer according to claim 13 having a molecular weight ranging from 2,500 to 7,000.
15. A diblock copolymer according to any one of claims 1 to 14 being a liquid at room temperature or at 37°C.
- 30
16. A composition comprising an active ingredient and one or more diblock copolymers of formula A-B according to any one of claims 1 to 15 characterized in that the composition is liquid below 50°C.
- 35
17. A composition according to claim 16 wherein the composition is non-aqueous.
18. A pharmaceutical dosage form comprising a therapeutically effective amount of a

composition according to claim 16 or 17.

19. A pharmaceutical dosage form according to claim 18 characterized in that the dosage form is suitable for oral administration.

5

20. A pharmaceutical dosage form according to claim 18 characterized in that the dosage form is suitable for parenteral administration.

10

21. A pharmaceutical dosage form according to any one of claims 18 to 20 wherein the dosage form is an aqueous solution.

15

22. A process to prepare an aqueous solution comprising an active ingredient and one or more diblock copolymers of formula A-B according to any one of claims 1 to 15 characterized by mixing the active ingredient with the one or more liquid copolymers, i.e. at a temperature below 50°C, followed by addition of water while stirring.

20

23. A process to prepare an aqueous solution comprising an active ingredient and one or more diblock copolymers of formula A-B according to any one of claims 1 to 15 characterized by

a) mixing the one or more copolymers with water at a temperature below 50°C, followed by

b) the addition of the active ingredient to the aqueous polymeric solution obtained under a) while stirring.

25

24. Use of a composition according to claim 16 or 17 for the manufacture of a pharmaceutical dosage form for oral administration to a human or non-human animal in need of treatment.

30

25. Use of a composition according to claim 16 or 17 for the manufacture of a pharmaceutical dosage form for parenteral administration to a human or non-human animal in need of treatment.

35

26. A pharmaceutical package suitable for commercial sale comprising a container, a pharmaceutical dosage form according to any one of claims 18 to 21, and associated with said package written matter.